Merck & Co., Inc.

1. 01

   Ahead of SPY and its sector fund XLV over 1 year

   1 month: +3.7% (SPY −2.6%, XLV +9.9%). 3 months: +13.0% (SPY −2.2%, XLV +13.5%). 1 year: +75.4% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: MRK, SPY and XLV · as of 3 Nov 2026

2. 02

   P/E 2.8× its peers' median

   Trailing P/E of 115.1 against a median of 41.1 across 5 peers named in its company record (range 14.0 to 81.6).

   Quote feed P/E (price ÷ trailing 12-month EPS); peers as named in the company record · as of 3 Nov 2026

3. 03

   Below its 50-day average, above its 200-day

   The 3 Nov 2026 close of $144.67 was 1.4% below its 50-day average ($146.66) and 13.8% above its 200-day average ($127.07). It has closed above the 200-day for 250 sessions, since 5 Nov 2025. The 50-day average crossed above the 200-day on 30 Oct 2025, 253 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026

4. 04

   83% of the way up its 52-week range

   Closed at $144.67 on 3 Nov 2026: 7.8% below the 52-week high of $156.92 (25 Aug 2026) and 74.5% above the low of $82.91 (5 Nov 2025).

   Daily price bars, split-adjusted · as of 3 Nov 2026

5. 05

   Short interest at 1.1% of shares outstanding

   26.8M shares were sold short at the 15 Oct 2026 settlement, 1.1% of the 2.47B shares outstanding; covering them would take 3.0 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

At the 3 Nov 2026 close